Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244065 | 1.00 | CYP2A6 (0.61) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL8975209 | 1.00 | CYP2A6 (0.61) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL4958248 | 0.95 | TDP1 (0.62) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL22229849 | 0.89 | CHRNA7 (0.58) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL7474917 | 0.89 | CHRNA7 (0.58) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL9519417 | 0.87 | CYP2A6 (0.57) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL9519412 | 0.87 | CYP2A6 (0.57) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL12197971 | 0.86 | TDP1 (0.62) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL3927981 | 0.86 | CYP2A6 (0.65) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| Bromide SCHEMBL18838899 | 0.84 | TDP1 (0.61) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0404146-B1 | Enantiomeric enrichment and stereoselective synthesis of chiral amines | CELGENE CORP (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0656004-A1 | DUAL FUNCTIONAL ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE AGENTS | CYTOMED, INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994004537-A2 | DUAL FUNCTIONAL ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE AGENTS | CYTOMED, INC. (US) | 1994-03-03 | — | — | WO | disclosed |
| EP-0299379-B1 | PENTADIENAMIDE PAF-ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-21 | — | — | EP | disclosed |
| US-5169780-A | Conversion to ketone in aqueous solution with amino acceptor and omega-amino acid acceptor; solvent extraction | CELGENE CORPORATION (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0404146-A2 | Enantiomeric enrichment and stereoselective synthesis of chiral amines | CELGENE CORPORATION (US) | 1990-12-27 | — | — | EP | disclosed |
| US-4975438-A | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. (US) | 1990-12-04 | — | — | US | disclosed |
| US-4927826-A | Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists | HOFFMAN-LA ROCHE INC. (US) | 1990-05-22 | — | — | US | disclosed |
| US-4927838-A | CARDIOVASCULAR DISORDERS | HOFFMAN-LA ROCHE INC. (US) | 1990-05-22 | — | — | US | disclosed |
| US-4916145-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0299379-A1 | Pentadienamide PAF-antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-18 | — | — | EP | disclosed |
| EP-0298466-A2 | Substituted alkene carboxylic acid amides and derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-11 | — | — | EP | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4786646-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-22 | — | — | US | disclosed |